CDER Office of Pharmaceutical Quality’s Rachel Novak provides an overview of the 351(k) pathway, shares the agency’s expectations for manufacturing of biosimilar products at licensure, and identifies potential road blocks to approvability related to the manufacturing of biosimilar products.
Learn more at: [ Ссылка ]
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Visit [ Ссылка ] and [ Ссылка ] for news and a repository of training activities.
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367
LinkedIn: [ Ссылка ]
Twitter: [ Ссылка ]
CDER small business e-mail update subscription: [ Ссылка ]
